OncoMed: ASCO GI 2016 (OncoMed) - Jan 27, 2016 - Anticipated completion of enrollment in P2 YOSEMITE trial (NCT02289898) in combination with gemcitabine and Abraxane for pancreatic cancer in 2016; Anticipated data from P2 YOSEMITE trial (NCT02289898) in combination with gemcitabine and Abraxane for pancreatic cancer in early 2017
Anticipated enrollment status • Anticipated P2 data • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer
|